胆管癌组织紧密连结蛋白18、丝氨酸蛋白酶抑制剂和p53蛋白表达及其临床意义

doi:10.3969/j.issn.1672-5069.2017.03.014

摘要/Abstract

摘要： 目的探讨胆管癌组织紧密连结蛋白18（claudin-18）、丝氨酸蛋白酶抑制剂（maspin）和p53蛋白表达的临床意义。方法采用免疫组化和Western blot法检测46例胆管癌和32例正常胆管组织claudin-18、maspin和p53蛋白的表达,采用Spearman等级相关分析。结果胆管癌组织claudin-18和p53蛋白阳性率分别为52.17%和56.52%,显著高于正常胆管组织（0.0%和0.0%,P<0.01）;胆管癌组织maspin阳性率为86.96%,显著低于正常胆管组织（100.0%,P<0.01）;胆管癌组织claudin-18、maspin和p53蛋白表达量分别为2.83±0.52、2.45±1.24和1.73±1.26,均显著高于正常胆管组织（0.48±0.75、0.46±0.32和0.0±0.0,P<0.05）;胆管癌组织maspin与p53表达呈负相关（r=-8.546,P=0.001）。结论胆管癌组织maspin、claudin-18和p53蛋白表达的意义还有待于进一步研究。

关键词: 胆管癌, 紧密连结蛋白18, 丝氨酸蛋白酶抑制剂, p53, 免疫组化, 蛋白印迹法

Abstract: Objective To study the expression of claudin-18,maspin and p53 in tissues of cholangiocarcinoma. Methods The expression of claudin-18,maspin and p53 were detected by immunohistochemistry and Western blot in 46 cholangiocarcinoma and 32 normal liver tissues. Result The positive rates of claudin-18 and p53 in cancerous tissues were 52.17% and 56.52%,respectively,significantly higher than 0.0% and 0.0% in normal control（P<0.01）;The positive rate of maspin in cancerous tissues was 86.96%,much lower than 100.0% in normal control（P<0.01）;The relative expression levels of claudin-18,maspin and p53 were 2.83±0.52, 2.45±1.24 and 1.73±1.26, respectively,significantly higher than 0.48±0.75,0.46±0.32 and 0.0±0.0 in the control （P<0.05）;The expression of maspin was negatively correlated with p53 expression in cancerous tissues（r=-8.546,P=0.001）. Conclusion The implication of maspin,claudin-18 and p53 expression in cholangiocarcinoma tissues needs further investigation.

Key words: Cholangiocarcinoma, Claudin-18, Maspin, p53, Immunohistochemistry, Western blot

曹光材, 白江江, 戴阿利. 胆管癌组织紧密连结蛋白18、丝氨酸蛋白酶抑制剂和p53蛋白表达及其临床意义[J]. 实用肝脏病杂志, 2017, 20(3): 312-315.

Cao Guangcai, Bai Jiangjiang, Dai Ali. Expression of claudin-18, maspin and p53 in tissues from cholangiocarcinoma[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2017, 20(3): 312-315.

参考文献

[1] Xie D,Ren Z,Fan J,et al.Genetic profiling of intrahepatic cholangiocarcinoma and its clinical implication in targeted therapy. Am J Cancer Res,2016,6(3):577-586.
[2] Kaira K,Sunose Y,Ohshima Y,et al.Clinical significance of L-type amino acid transporter 1 expression as a prognostic marker and potential of new targeting therapy in biliary tract cancer. BMC Cancer,2013,13(1):5123-5128.
[3] Ercan C,Diest PJV,Ende BVD,et al.p53 mutations in classic and pleomorphic invasive lobular carcinoma of the breast. Cell Oncol,2012,35(2):111-118.
[4] Merikallio H,Paakko P,Harju T,et al.Claudins 10 and 18 are predominantly expressed in lung adenocarcinomas and in tumors of nonsmokers. Int J ClinExperiment Pathol,2011,4(7):667-673.
[5] Lee DY,Park CS,Kim HS,et al.Maspin and p53 protein expression in gastric adenocarcinoma and its clinical applications. App Immunohistochem Mol Morphol Aimm,2008,16(1):13-18.
[6] Hsu M.KRAS and GNAS mutations and p53 overexpression in biliary intraepithelial neoplasia and intrahepatic cholangiocarcinomas. Cancer,2013,119(9):1669-1674.
[7] Keira Y,Takasawa A,Murata M,et al.An immunohistochemical marker panel including claudin-18,maspin,and p53 improves diagnostic accuracy of bile duct neoplasms in surgical and presurgical biopsy specimens. Archiv Für Pathologische Anatomie Und Physiologie Und Für Klinische Medicin,2015,466(3):265-277.
[8] 刘英杰,桂淑玉,周青,等. Claudin-18 蛋白在肺腺癌所致恶性胸腔积液中的表达及临床意义. 安徽医科大学学报,2014,49(12):1788-1791.
[9] Soini Y,Takasawa A,Eskelinen M,et al.Expression of claudins 7 and 18 in pancreatic ductal adenocarcinoma:association with features of differentiation. J Clin Pathol,2012,65(5):431-436.
[10] Rho SY,Bae SU,Baek SJ,et al.Feasibility and safety of laparoscopic resection following stent insertion for obstructing left-sided colon cancer. J Kor Surg Soc,2013,85(6):290-295.
[11] Webber BA,Lawson D,Cohen C.Maspin and Mutant p53 expression in malignant melanoma and carcinoma:use of tissue microarray. AppImmunohistochem Mol Morphol Aimm,2008,16(1):19-23.
[12] Payne CM,Holubec H,Crowley-Skillicorn C,et al.Maspin is a deoxycholate-inducible,anti-apoptotic stress-response protein differentially expressed during colon carcinogenesis. Clin Exp Gastroenterol,2011,4(1):239-253.
[13] Prica F,Radon T,Cheng Y,et al.The life and works of S100P-from conception to cancer. Am J Cancer Res,2016,6(2):562-576.
[14] Secord AA,Darcy KM,Hutson A,et al.The regulation of MASPIN expression in epithelial ovarian cancer:Association with p53 status,and MASPIN promoter methylation:A Gynecologic Oncology Group study. Gynecol Oncol,2011,123(2):314-319.
[15] Santer FR,Malinowska K,Culig Z,et al.Interleukin-6 trans-signalling differentially regulates proliferation,migration,adhesion and maspin expression in human prostate cancer cells. Endocr Relat Cancer,2010,17(1):241-253.
[16] Yanagisawa N,Hana K,Nakada N,et al.High expression of L-type amino acid transporter 1 as a prognostic marker in bile duct adenocarcinomas. Cancer Med,2014,3(5):1246-1255.
[17] Joerger AC,Fersht AR.The tumor suppressor p53:from structures to drug discovery. Cold Spring Harbor Perspect Biol,2010,2(6):968-976.
[18] Glanzer JG,Carnes KA,Soto P,et al.A small molecule directly inhibits the p53 transactivation domain from binding to replication protein A. Nucl Acids Res,2013,41(3):2047-2059.
[19] 戚峰,邰升,苏志雷. p33ING1b与p53在胆管癌中的表达及临床意义. 中国现代普通外科进展,2015,18(7):509-512.
[20] Shinozaki A,Shibahara J,Noda N,et al.Claudin-18 in biliary neoplasms. Its significance in the classification of intrahepatic cholangiocarcinoma. Virchows Archiv,2011,459(1):73-80.